Health service and government policies on the licensing, provision and reimbursement of oral pre-exposure prophylaxis (PrEP). Expert guidelines, based on research evidence, to help clinicians provide care to PrEP users.

PrEP policies and guidelines: latest news

PrEP policies and guidelines features

PrEP policies and guidelines news from aidsmap

  • What’s the relationship between PrEP, condom use and STIs?

    HIV experts and professionals agree that pre-exposure prophylaxis (PrEP) is a valuable addition to HIV prevention, but have varied views of the relationship between PrEP, reduced condom use and sexually transmitted infections (STIs), according to a study published last month ...

    17 July 2019 | Roger Pebody
  • Nine HIV diagnoses in men on PrEP waiting list, Manchester

    Nine gay men are known to have seroconverted since being put on a waiting list for pre-exposure prophylaxis (PrEP) at a single Manchester clinic, Dr Sally Jewsbury told the British Association for Sexual Health and HIV (BASHH) conference in ...

    01 July 2019 | Roger Pebody
  • US insurers must now cover PrEP

    An influential guidelines body in the United States has put its full weight behind pre-exposure prophylaxis (PrEP) to people at high risk of HIV. The grade A recommendation of the United States Prevention Services Task Force (USPSTF), published in ...

    11 June 2019 | Roger Pebody
  • PrEP should be offered urgently to gay men with a recent STI or multiple condomless partners

    Analysis of men who acquired HIV in the deferred arm of the PROUD study highlights two risk factors that are far more important than any others. “A recent history of syphilis or rectal chlamydia/gonorrhoea, or multiple ncRAI [receptive anal ...

    15 April 2019 | Roger Pebody
  • First year of PrEP in Scotland: more users than expected, few dropouts, few HIV infections

    The recent report on the first year of the implementation of  pre-exposure prophylaxis (PrEP) through the National Health Service (NHS) in Scotland concludes: “Year one has been a resounding success in terms of establishing a new nationwide service ...

    02 April 2019 | Gus Cairns
  • PrEP promotion should be positive and inclusive

    Pre-exposure prophylaxis (PrEP) programmes should adopt modern marketing strategies that are attractive to healthy individuals and that might promote an inclusive and holistic vision of PrEP, Dr K Rivet Amico and Professor Linda-Gail Bekker argue in an opinion ...

    25 January 2019 | Roger Pebody
  • How did Kenya build Africa’s largest PrEP programme?

    Around 25,000 people are taking pre-exposure prophylaxis (PrEP) in Kenya, making it Africa’s largest PrEP programme, ahead of South Africa (9000 people), Uganda (4000) and Zimbabwe (4000). The roll-out was recently described by officials from Kenya’s Ministry of Health ...

    25 January 2019 | Roger Pebody
  • Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men

    A study presented at last month’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in ...

    09 November 2018 | Gus Cairns
  • Some gay and bisexual men see PrEP as a 'social problem'

    Gay and bisexual men have differing attitudes towards men who are using pre-exposure prophylaxis (PrEP), according to US research published in Sociology of Health & Illness. A series of focus groups conducted in New York City showed that some ...

    05 October 2018 | Michael Carter
  • Most PrEP users in Berlin obtained it from informal channels

    Over half of men who have sex with men (MSM) living in Berlin who were using HIV pre-exposure prophylaxis (PrEP) accessed it through informal sources, without consistent medical monitoring, according to a recent study published in PLOS ONE. The results ...

    02 October 2018 | Krishen Samuel
More news

PrEP policies and guidelines news selected from other sources

  • Are 2 million bottles of PrEP an empty gesture?

    Gilead should either commit to providing all the doses of PrEP required for everyone who would benefit or open the market up to a range of generic manufacturers.

    15 July 2019 | The Lancet HIV
  • In New York City, PrEP on Demand Is Now on the Menu for Men Who Have Sex With Men

    For a long time, the most common way to describe pre-exposure prophylaxis (PrEP) was that it is a daily pill taken to prevent acquiring HIV. But now, New York City is tackling what might be a barrier to PrEP uptake with its new on-demand PrEP initiative.

    11 July 2019 | The Body Pro
  • Insurance Will Soon Cover HIV Prevention, But Many People Who Need it Still Won't Have Access

    When Corey Walsh began using the drug Truvada, the pills were free but the quarterly lab tests and doctors' visits cost almost $400.

    11 July 2019 | Vice
  • Same-day PrEP initiation a favorable option for patients at risk for HIV

    Same-day initiation of pre-exposure prophylaxis, or PrEP, for HIV prevention was found to be safe, feasible and well-received among patients at a walk-in STD clinic, according to a recently published study. During the study, which was conducted at a clinic in Denver, a high proportion of the participants were linked to ongoing PrEP care, researchers reported.

    10 July 2019 | Healio
  • NHS England recommends uncapped PrEP trial access

    NHS England have announced five steps towards better access to the HIV prevention drug PrEP, including recommending removing the capped number of places on the ongoing IMPACT Trial. This follows a meeting yesterday between Simon Stevens, chief executive of NHS England, NAT (National AIDS Trust), Terrence Higgins Trust, and PrEPster.

    08 July 2019 | National Health Executive
  • What Does PrEP Cost Outside the United States?

    For the past several years, doctors in the United States have watched enviously as other countries have approved generic versions of PrEP made by Mylan, Teva, and other generic drug companies. These cheaper generics have made it easier for governments to support large PrEP scale-up programs.

    04 July 2019 | The Body
  • HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?

    On Tuesday, the Department of Health and Human Services was awarded a new patent that broadly covers medicines derived from tenofovir and used to prevent HIV.

    03 July 2019 | STAT
  • FDA Eliminates REMS for HIV Drug Truvada and its Generics

    The US Food and Drug Administration (FDA) announced late Monday that it would eliminate the risk evaluation and mitigation strategy (REMS) for Gilead's Truvada (emtricitabine/tenofovir disoproxil fumarate) and its four approved generics, which reduce the risk of sexually acquired HIV.

    02 July 2019 | Regulatory Focus
  • USPSTF PrEP Recommendation a Major Step Forward, but Not a Silver Bullet

    The new ruling theoretically means patients will be able to access the drug without being exposed to high costs—or any costs, for that matter. However, it’s unclear how insurers will implement the USPSTF’s recommendations. That’s because, while on paper their requirements are straightforward, there are a number of variables available to insurers that might impact patients’ ability to access the drug.

    01 July 2019 | Contagion Live
  • Advocates find Harris PrEP bill lacking

    Senator Kamala Harris (D-California) last week introduced legislation that would expand access to PrEP by requiring public and private health insurers to cover it and funding a grant program for uninsured individuals. But some advocates say Harris needs to work with the community to develop a better plan.

    01 July 2019 | Bay Area Reporter
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.